# Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

> **NCT04562532** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai MicroPort Medical (Group) Co., Ltd.** · enrollment: 1720 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** Microport Firehawk stent
- **DEVICE:** 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)

## Key facts

- **NCT ID:** NCT04562532
- **Lead sponsor:** Shanghai MicroPort Medical (Group) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-17
- **Primary completion:** 2023-12-10
- **Final completion:** 2027-06-30
- **Target enrollment:** 1720 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562532, "Firehawk Rapamycin Target Eluting Coronary Stent North American Trial". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04562532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*